Study comparing siplizumab to another drug for kidney transplant acceptance
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a kidney transplant from a living or deceased donor that is not a perfect tissue match.
- The donor kidney must have been stored for less than 30 hours before transplant.
- If you are able to become pregnant, you must agree to use highly effective birth control.
- You must not have had a positive test for donor-specific antibodies before transplant.
- You cannot have had a previous kidney transplant or a transplant of another organ.
- You must not be taking certain immune-suppressing drugs or have certain infections like HIV or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This study tests a new combination of medicines (Sip-Tego) to help your body accept a living donor kidney without needing lifelong anti-rejection drugs. It is for people with advanced kidney failure who are getting a first or second transplant.
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
Hear when a new Renal Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.